Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 20 Brain Neoplasms 10 Glioblastoma 5 Glioma 4 Neoplasms 3 Uterine Cervical Neoplasms 2 Urogenital Diseases 2 Disease 2 Uterine Neoplasms 1 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Prostate Adenocarcinoma 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Multiple Myeloma 1 Metastatic Castration-resistant Prostate Cancer 1 Lymphoma, Follicular 1 Endometrial Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Lobular 1 Breast Neoplasms 1

Interventions

Dexamethasone 809 Bortezomib 449 Lenalidomide 430 Cyclophosphamide 336 Melphalan 251 Calcium Dobesilate 237 daratumumab 218 pomalidomide 202 carfilzomib 181 fludarabine phosphate 131 Thalidomide 121 fludarabine 118 Peripheral Blood Stem Cell Transplantation 117 Filgrastim 111 ixazomib 85 Mycophenolic Acid 85 Granulocyte Colony-Stimulating Factor 84 Busulfan 83 Whole-Body Irradiation 80 Tacrolimus 75 dexamethasone acetate 74 Cyclosporine 67 isatuximab 64 Prednisone 64 dexamethasone 21-phosphate 63 elotuzumab 60 auricularum 57 belantamab mafodotin 55 Antilymphocyte Serum 55 Etoposide 52

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Multiple Myeloma × fluciclovine F-18 × Clear all

NCT06103838 2026-05-29

18F-Fluciclovine PET/CT in Multiple Myeloma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡